Please assess the completion status of the following clinical trial:

Trial Title: Optimization of the Dosage Regimen of Growth Hormone Therapy in Children Born Small for Gestational Age

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~To be eligible for inclusion / randomization into this study, the subjects must fulfill all of the following criteria (if there is no inclusion phase, the inclusion criteria will be considered as inclusion criteria for randomization):~* Written consent form signed by the parents / legal guardian, and child if possible~* Subject born SGA and receiving a r-hGH therapy for this pathology~* Recombinant human growth hormone (r-hGH) started at the maximal chronological age of 7 years for girls and 8 years for boys~* Treatment with r-hGH started for at least 30 months and less than 36 months at 0.057 mg/kg/day~* Height gain during the first 2 years of GH treatment \> 1 SD compared with the initial value~Exclusion Criteria:~To be eligible for inclusion in this study the subjects must not meet any of the following criteria:~* Known hypersensitivity to Somatropin or any of the excipients~* Active neoplasia (either newly diagnosed or recurrent)~* Intracranial hypertension~* Known diabetes mellitus~* Proliferative or preproliferative diabetic retinopathy~* Evidence of any progression or recurrence of an underlying intra-cranial space occupying lesion~* Obesity defined as degree 1 on the corpulence curves~* Precocious puberty~* Pubertal status: Tanner breast development stage \> 2 for girls, and testicular volume \> 4 milliliter (mL) or testicular length \> 3 centimeter (cm) and/or testosterone value \>1 nanomole/liter \[nmol/L\] (0.29 gram/mL \[g/mL\]) for boys For girls \> 9 years and Tanner breast development stage 1: uterine size \> 35 millimeter (mm)~* Severe chronic concomitant illness such as chronic renal failure, cystic fibrosis~* Concomitant corticoid treatment or levothyroxine treatment other than substitutive treatment, topical or inhaled treatment~* Participation to any clinical study within the 30 days preceding study entry

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: 11 Years
- Healthy Volunteers: f

Study Arms:
- Saizen® 0.057 mg/kg/day (Type: EXPERIMENTAL): Subjects who met all inclusion/exclusion criteria were randomly assigned to 0.057 mg/kg/day in this multi-center study. Subjects were stratified at randomization according to the Height-Standard Deviation Score (H-SDS) at this time (less than \[\<\] -2 SDS or greater than \[\>\] -2 SDS)
- Saizen® 0.035 mg/kg/day (Type: EXPERIMENTAL): Subjects who met all inclusion/exclusion criteria were randomly assigned to 0.035 mg/kg/day in this multi-center study. Subjects were stratified at randomization according to the H-SDS at this time (\< -2 SDS or \> -2 SDS)

Based on this trial design, predict the completion outcome and termination type (if applicable).